ITM Executes Option to In-license Targeted Radionuclide Therapy Candidate LuCaFab (ITM-31) for ...
bdtonline.com
news
2022-10-19 12:04:20

Exclusive license from Helmholtz Munich will enable ITM to access IP and know-how to develop and commercialize ITM-31 for glioblastoma patientsGarching/Munich, Germany, October 19, 2022 â€“ ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, today announced the execution of an exclusive licensing option for LuCaFab (now ITM-31), a novel Targeted Radionuclide Therapy candidate for the treatment of malignant glioblastoma. ITM-31 is a carbonic anhydrase XII (CA XII)-specific antibody Fab fragment developed by Helmholtz Munich and coupled with ITM's medical radioisotope, non-carrier-added Lutetium-177 (n.
